Sweden · Delayed Price · Currency is SEK LIDDS AB Company Description
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden.
Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer.
The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments.
It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication.
The company was incorporated in 1999 and is based in Stockholm, Sweden.
| Country | Sweden |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Mats Wiking |
Contact Details
Address: Box 12040 Stockholm, 112 40 Sweden | |
| Website | liddspharma.com |
Stock Details
| Ticker Symbol | LIDDS |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0001958612 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mats Bjorn Wiking | Chief Executive Officer, Chief Financial Officer and Head of IR |
| Monica Wallter | Senior Advisor |
| Kia Bengtsson | Head of Clinical Development |